此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

瘤内注射 PH-762 用于治疗皮肤癌

2026年9月16日 更新者:Phio Pharmaceuticals Inc.

新辅助瘤内注射 PH-762 治疗皮肤鳞状细胞癌、黑色素瘤或默克尔细胞癌的剂量递增研究

The goal of this clinical trial is to evaluate the safety and tolerability of intratumoral injections of PH-762 in squamous cell carcinoma, melanoma, or Merkel cell carcinomas of the skin, to understand what the body does to the PH-762, and to observe how the tumor responds to the drug. Participants will receive four injections of PH-762 at weekly intervals, into a single tumor, followed by surgical removal of the tumor approximately two weeks later.

研究概览

详细说明

PH-762 is a potent RNAi molecule targeting PD-1. PH-762 can inhibit the immune checkpoint PD-1 in the tumor and thereby impede tumor growth. As a preoperative therapy, it may decrease the lesion size and has the potential to improve surgical morbidity. Intratumoral immunotherapy aims to use the tumor as a 'self-vaccine'. The local immune stimulation can induce robust priming of an anti-tumor immune response while generating systemic (abscopal) tumor responses, mediated by properly activated anti-tumor immune cells in the circulation. Local delivery of immunotherapy is expected to minimize systemic exposure and off-target toxicities.

This is a non-comparative study of neoadjuvant monotherapy using PD-1 targeting self-delivering RNAi (PH-762) in adult subjects with cutaneous squamous cell carcinoma, melanoma, or Merkel cell carcinoma. The study treatment consists of four intratumoral injections of PH-762 at weekly intervals, into a single tumor lesion. Excision of the tumor will occur approximately two weeks following the fourth dose of IT PH-762, and the subjects will be followed for an additional 11 weeks.

研究类型

介入性

注册 (实际的)

22

阶段

  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Arizona
      • Gilbert、Arizona、美国、85234
        • Banner MD Anderson Cancer Center
    • California
      • San Diego、California、美国、92108
        • Paradigm Clinical Research
    • Florida
      • Delray Beach、Florida、美国、33445
        • Integrity Research
    • Nevada
      • Reno、Nevada、美国、89509
        • Skin Cancer and Dermatology Institute
    • Ohio
      • Columbus、Ohio、美国、43213
        • Centricity Research

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Key Inclusion Criteria:

  • Histologically confirmed cutaneous squamous cell carcinoma (cSCC), melanoma, or Merkel cell carcinoma, meeting one of the following criteria:

    • cSCC, resectable local tumors: must be Stage II or lower, amenable to curative resection and in a location where acceptable surgical margins are anticipated
    • cSCC, unresectable local tumors: must be Stage II or lower, tumor has been unresponsive to prior radiation therapy or is not a candidate for curative radiation therapy
    • cSCC, metastatic disease: disease has progressed during or following prior checkpoint inhibitor therapy (anti-PD-1 or anti-PD-L1 antibody)
    • Melanoma, metastatic disease: Stage IV disease with a cutaneous lesion that has progressed during or following checkpoint inhibitor therapy (anti-PD-1/-PD-L1), and if BRAF-mutation is present, has progressed during or following prior treatment with anti-BRAF + MEK therapy
    • Merkel cell carcinoma, metastatic disease: Stage IV disease with a cutaneous lesion that has progressed during or following checkpoint inhibitor therapy (anti-PD-1/PD-L1)
  • A minimum of one tumor of ≥ 1.0 cm and < 3.0 cm in longest dimension that is accessible (with or without imaging guidance) for intratumoral injection and for biopsy and surgical excision must be present. The tumor is not necrotic, hemorrhagic, or friable, and is not within 2 cm of the eye or within 0.5 cm of or on the lip (including the vermilion border) and is not in a mucosal or visceral location.

Key Exclusion Criteria:

  • Other malignancy within prior 3 years, with certain exceptions.
  • Current cancer chemotherapy, radiation therapy, immunotherapy, or biologic therapy.
  • Any serious or uncontrolled medical disorder including auto-immune disease that may increase the risk associated with study participation or study drug administration, or interfere with the interpretation of study results.
  • Females who are pregnant or are breastfeeding.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Sequential escalating doses of PH-762.

Escalating doses of PH-762 are to be tested, with an observation period between doses.

PH-762 is a potent RNAi molecule targeting PD-1.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Adverse Events
大体时间:16 weeks

Incidence, severity, seriousness and relatedness of all treatment-emergent adverse events.

16 weeks

次要结果测量

结果测量
措施说明
大体时间
Pharmacokinetics: maximum plasma concentration (Cmax)
大体时间:3.5 weeks

Maximum concentration of PH-762 following intratumoral injection.

3.5 weeks
Pharmacokinetics: time to maximum plasma concentration (Tmax)
大体时间:3.5 weeks

Time to maximum concentration of PH-762 following intratumoral injection.

3.5 weeks
Pharmacokinetics: area under the curve to last quantifiable plasma concentration (AUClast)
大体时间:3.5 weeks

Exposure to PH-762 through last quantifiable concentration following intratumoral injection.

3.5 weeks
Pathologic response
大体时间:5 weeks

Pathological response will be assessed by relative amount of viable tumor in resection specimens of the treated lesion.

5 weeks
Tumor burden
大体时间:5 weeks

Change in tumor burden will be assessed per RECIST/ iRECIST guidelines for the treated lesion.

5 weeks

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

合作者

调查人员

  • 研究主任:Linda Mahoney、Phio Pharmaceuticals Inc.

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2023年11月7日

初级完成 (实际的)

2025年12月29日

研究完成 (实际的)

2026年3月17日

研究注册日期

首次提交

2023年8月22日

首先提交符合 QC 标准的

2023年8月25日

首次发布 (实际的)

2023年8月28日

研究记录更新

最后更新发布 (实际的)

2026年9月21日

上次提交的符合 QC 标准的更新

2026年9月16日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅